Abstract
The MCI construct aims to investigate the grey area existing between normal aging and dementia, in order to identify in the preclinical stage patients at risk of developing dementia. The construct of the MCI has been proposed by taking the neuropathological staging of the Alzheimers disease (AD) as reference and providing an explicit set of identifying criteria, but it has raised two main problems: (a) the variability of estimates concerning the actual rate of conversion from MCI to dementia, and (b) the number of subjects who return to normality. These problems stem in part from the operational difficulties met by the MCI identifying criteria concerned with: the memory tests used, the cut-off adopted to identify patients with an ‘objective’ memory disorder, the assessment of subjective memory disorders, and the integrity of daily living activities. After a short discussion of these operational difficulties, I will pass to shortly survey the laboratory data providing additional predictive value for the conversion of MCI to dementia (ApoE4, CSF biomarkers, Neuroimaging data, and Vascular risk factors) and some recent attempts to identify pre-MCI patients, with a purely subjective cognitive impairment. I will conclude my review by asking if we have a single MCI or a family of MCI constructs, each of whom could play a preferential role in specific clinical contexts.
Keywords: Conversion to dementia, return to normality, delayed recall, cut-off points, subjective memory disorders, daily living activities, subjective cognitive impairment
Current Alzheimer Research
Title: Origins, Controversies and Recent Developments of the MCI Construct
Volume: 7 Issue: 3
Author(s): G. Gainotti
Affiliation:
Keywords: Conversion to dementia, return to normality, delayed recall, cut-off points, subjective memory disorders, daily living activities, subjective cognitive impairment
Abstract: The MCI construct aims to investigate the grey area existing between normal aging and dementia, in order to identify in the preclinical stage patients at risk of developing dementia. The construct of the MCI has been proposed by taking the neuropathological staging of the Alzheimers disease (AD) as reference and providing an explicit set of identifying criteria, but it has raised two main problems: (a) the variability of estimates concerning the actual rate of conversion from MCI to dementia, and (b) the number of subjects who return to normality. These problems stem in part from the operational difficulties met by the MCI identifying criteria concerned with: the memory tests used, the cut-off adopted to identify patients with an ‘objective’ memory disorder, the assessment of subjective memory disorders, and the integrity of daily living activities. After a short discussion of these operational difficulties, I will pass to shortly survey the laboratory data providing additional predictive value for the conversion of MCI to dementia (ApoE4, CSF biomarkers, Neuroimaging data, and Vascular risk factors) and some recent attempts to identify pre-MCI patients, with a purely subjective cognitive impairment. I will conclude my review by asking if we have a single MCI or a family of MCI constructs, each of whom could play a preferential role in specific clinical contexts.
Export Options
About this article
Cite this article as:
Gainotti G., Origins, Controversies and Recent Developments of the MCI Construct, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050858
DOI https://dx.doi.org/10.2174/156720510791050858 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Long-Term Effects of Intracerebroventricular Streptozotocin Treatment on Adult Neurogenesis in the Rat Hippocampus
Current Alzheimer Research 3,4-Dihydrospiro[piperidine-4,2-(1H)quinoline] Derivatives as New Antioxidant Agents with Acetylcholinesterase Inhibitory Property
Letters in Drug Design & Discovery Overview and Findings from the Rush Memory and Aging Project
Current Alzheimer Research Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Current Alzheimer Research Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Association of Folate Level in Blood with the Risk of Schizophrenia
Combinatorial Chemistry & High Throughput Screening Synthesis of Chiral 2-(6,8-dichloro-4-methyl-1,1,3-trioxo-3,4-dihydro-1H-1λ6-benzo[1,2,4]thiadiazin-2-yl) Carboxylic Acids Derived from Enantiomeric Amino Acids
Letters in Organic Chemistry Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design